Additionally, the SOUL trial like Flow is evaluating the effectiveness of semaglutide in reducing severe renal outcomes and cardiovascular mortality in T2D patients, potentially establishing GLP1-RAs as foundational in protecting both kidney and heart health. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.